Linking the Legacy Effect in Type 2 Diabetes to Clinical Decision Making

将 2 型糖尿病的遗留影响与临床决策联系起来

基本信息

  • 批准号:
    8425302
  • 负责人:
  • 金额:
    $ 17.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Observational follow-up of the landmark United Kingdom Prospective Diabetes Study revealed that early tight glycemic control had persistent benefits among adults with newly diagnosed diabetes even a decade after the trial had ended. This phenomenon has been dubbed the "legacy effect" of glycemic control and has not been observed for blood pressure control. The existence of the legacy effect implies that the timing of glycemic control, for example, early vs. late in the disease course, may have clinical consequences. This raises new fundamental diabetes translational research questions. In clinical practice, how soon after diagnosis do patients achieve hemoglobin A1C (A1C) and blood pressure (BP) control and for how long? How do different long-term patterns of control affect future health outcomes? And what do patients believe regarding how and when the timing of therapies to achieve A1C and BP control affects their health outcomes? I am an internist who is committed to exploring whether the legacy effect exists in clinical practice and how to translate this novel observation from clinical trials into improved clinical care. Using a large, observationl cohort of adults from Kaiser Permanente Northern California with newly diagnosed diabetes (1995-2005), I will (Aim 1) characterize common patterns of a) A1C and b) BP control over e10 years of follow-up and (Aim 2) compare complications/mortality rates over e15 years of follow-up among patients with various 10-year patterns of a) A1C and b) BP control. Then in order to develop a theoretical model for how patients perceive the concept of time in their diabetes-related health decisions, I will conduct semi-structured interviews with patients with Type 2 diabetes to (Aim 3) explore their beliefs regarding the timing of A1C and BP control. The results of these studies will be used to inform a future R01 behavioral intervention focused on improving patient outcomes through effective risk communication and appropriately timed efforts to intensify A1C and BP control. During this career development award, I will work closely with my mentor, Dr. Elbert Huang, who is a nationally- recognized investigator in medical decision making for older adults with diabetes and Director of the Quantitative Analysis Core and Enrichment Programs of the Chicago Center for Diabetes Translation Research (P30) at the University of Chicago, and my co-mentor, Dr. Andrew Karter, an accomplished diabetes epidemiologist at Kaiser Permanente Northern California Division of Research, in addition to my advisory panel of leaders in longitudinal data analysis, endocrinology, health economics and behavioral psychology. This proposed research, along with additional training in advanced epidemiology, biostatistics and behavioral psychology, and the expertise of my mentorship team will help me achieve my long-term goal of becoming an independent clinical investigator with expertise in the optimal timing of Type 2 diabetes treatments and its risk communication. PUBLIC HEALTH RELEVANCE: Landmark diabetes trials have found that patients who achieved tight glycemic control early in their disease course have improved health outcomes long after the trial intervention had ended. No such "legacy effect" has been observed for blood pressure control. For the purposes of diabetes care translation, it is important to determine what long-term patterns of glycemic and blood pressure control are achieved in clinical practice, to establish whether a "legacy effect" exists in clinical practice, and to explore how these timing effects can be translated into improved patient care.
描述(由申请人提供):具有里程碑意义的英国前瞻性糖尿病研究的观察性随访显示,即使在试验结束十年后,早期严格的血糖控制对新诊断糖尿病的成年人也有持续的益处。这种现象被称为血糖控制的“遗留效应”,在血压控制中尚未观察到。遗留效应的存在意味着血糖控制的时机,例如病程的早期和晚期,可能会产生临床后果。这提出了新的基础性糖尿病转化研究问题。在临床实践中,患者在诊断后多久达到血红蛋白A1 C(A1 C)和血压(BP)控制以及多久?不同的长期控制模式如何影响未来的健康结果?患者对实现A1 C和BP控制的治疗时机如何以及何时影响他们的健康结果有何看法?我是一名内科医生,致力于探索临床实践中是否存在遗留效应,以及如何将临床试验中的这一新观察转化为改善的临床护理。使用来自北方加州Kaiser Permanente的新诊断糖尿病成年人的大型观察队列(1995-2005年),我将(目的1)描述10年随访期间a)A1 C和B)BP控制的常见模式,(目的2)比较15年随访期间a)A1 C和B)的各种10年模式患者的并发症/死亡率血压控制。然后,为了开发一个理论模型,患者如何感知时间的概念,在他们的糖尿病相关的健康决策,我将进行半结构化的采访与2型糖尿病患者(目的3)探索他们的信念,关于A1 C和BP控制的时间。这些研究的结果将用于为未来的R 01行为干预提供信息,该干预旨在通过有效的风险沟通和适当的时间努力来加强A1 C和BP控制,从而改善患者的结局。在这个职业发展奖期间,我将与我的导师埃尔伯特黄博士密切合作,他是一位全国公认的老年糖尿病患者医疗决策研究者,也是芝加哥大学芝加哥糖尿病转化研究中心(P30)定量分析核心和富集项目主任。他是凯萨医疗机构北方加州分部的一位有成就的糖尿病流行病学家,此外还有我的纵向数据分析、内分泌学、卫生经济学和行为心理学方面的顾问小组。这项拟议的研究,沿着在先进的流行病学,生物统计学和行为心理学的额外培训,以及我的导师团队的专业知识将帮助我实现我的长期目标,成为一名独立的临床研究者,在2型糖尿病治疗的最佳时机及其风险沟通方面具有专业知识。 公共卫生关系:具有里程碑意义的糖尿病试验发现,在病程早期实现严格血糖控制的患者在试验干预结束后很长时间内都能改善健康状况。对于血压控制,没有观察到这种“遗留效应”。对于糖尿病护理翻译的目的,重要的是要确定在临床实践中实现血糖和血压控制的长期模式,以确定在临床实践中是否存在“遗留效应”,并探索如何将这些时间效应转化为改善患者护理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neda Laiteerapong其他文献

Neda Laiteerapong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neda Laiteerapong', 18)}}的其他基金

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S)
实现患者结果报告的公平性,以便及时评估艾滋病毒感染者和药物使用的生活(ePORTAL HIV-S)
  • 批准号:
    10740440
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Predicting and Reducing Future Health Disparities for U.S. Adults with Diabetes
预测和减少美国成人糖尿病患者未来的健康差异
  • 批准号:
    9912648
  • 财政年份:
    2018
  • 资助金额:
    $ 17.61万
  • 项目类别:
Predicting and Reducing Future Health Disparities for U.S. Adults with Diabetes
预测和减少美国成人糖尿病患者未来的健康差异
  • 批准号:
    9788527
  • 财政年份:
    2018
  • 资助金额:
    $ 17.61万
  • 项目类别:
Patient Outcomes Reporting for Timely Assessments of Life with Depression: PORTAL-Depression
及时评估抑郁症生活的患者结果报告:门户抑郁症
  • 批准号:
    9753157
  • 财政年份:
    2018
  • 资助金额:
    $ 17.61万
  • 项目类别:
Linking the Legacy Effect in Type 2 Diabetes to Clinical Decision Making
将 2 型糖尿病的遗留影响与临床决策联系起来
  • 批准号:
    8538972
  • 财政年份:
    2012
  • 资助金额:
    $ 17.61万
  • 项目类别:
Linking the Legacy Effect in Type 2 Diabetes to Clinical Decision Making
将 2 型糖尿病的遗留影响与临床决策联系起来
  • 批准号:
    8878245
  • 财政年份:
    2012
  • 资助金额:
    $ 17.61万
  • 项目类别:
Linking the Legacy Effect in Type 2 Diabetes to Clinical Decision Making
将 2 型糖尿病的遗留影响与临床决策联系起来
  • 批准号:
    8704929
  • 财政年份:
    2012
  • 资助金额:
    $ 17.61万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10476594
  • 财政年份:
    2011
  • 资助金额:
    $ 17.61万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10290678
  • 财政年份:
    2011
  • 资助金额:
    $ 17.61万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10683200
  • 财政年份:
    2011
  • 资助金额:
    $ 17.61万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 17.61万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了